Post Marketing Study on Pluvicto in Korea

Recruiting · NCT06514521 · Observational (researchers observe without assigning treatment) · Lead sponsor: Novartis Pharmaceuticals

Interventions studied

Lutetium vipivotide tetraxetan

Post marketing study on Pluvicto in Korea

Age range

18 Years to 100 Years

Sex

Male

Healthy volunteers

No - a diagnosis or condition is required

Phase

Not specified

Study type

Observational (researchers observe without assigning treatment)

Study participants eligible for inclusion in this study must meet all of the following criteria:
Male adult patient age ≥ 18
Subject who are being treated with Pluvicto or whose treatment plan is finalized and scheduled to be administered at the time of consent by physician in accordance with the approved indication in South Korea
Subject who provided the written informed consent prior to the study enrollment

Study participants meeting any of the following criteria are not eligible for inclusion in this study:
Subject whose medical record is not accessible
Subject who is not willing to provide the informed consent

12 locations listed.